Walleye Capital LLC Purchases Shares of 44,652 Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Walleye Capital LLC bought a new stake in Entrada Therapeutics, Inc. (NASDAQ:TRDAGet Rating) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 44,652 shares of the company’s stock, valued at approximately $419,000. Walleye Capital LLC owned 0.14% of Entrada Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the business. Goldman Sachs Group Inc. purchased a new position in shares of Entrada Therapeutics in the 4th quarter valued at $130,560,000. Redmile Group LLC purchased a new position in shares of Entrada Therapeutics in the 4th quarter valued at $33,460,000. TCG Crossover Management LLC purchased a new position in shares of Entrada Therapeutics in the 4th quarter valued at $11,362,000. 72 Investment Holdings LLC purchased a new position in shares of Entrada Therapeutics in the 4th quarter valued at $8,714,000. Finally, Vanguard Group Inc. raised its stake in shares of Entrada Therapeutics by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 430,404 shares of the company’s stock valued at $4,041,000 after acquiring an additional 5,452 shares during the period. Hedge funds and other institutional investors own 79.02% of the company’s stock.

Insiders Place Their Bets

In other Entrada Therapeutics news, CEO Dipal Doshi sold 4,000 shares of the firm’s stock in a transaction on Monday, June 27th. The shares were sold at an average price of $12.00, for a total transaction of $48,000.00. Following the completion of the transaction, the chief executive officer now directly owns 210,710 shares of the company’s stock, valued at approximately $2,528,520. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CFO Kory James Wentworth sold 2,909 shares of Entrada Therapeutics stock in a transaction dated Tuesday, August 23rd. The shares were sold at an average price of $13.09, for a total value of $38,078.81. Following the completion of the transaction, the chief financial officer now directly owns 14,538 shares of the company’s stock, valued at approximately $190,302.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Dipal Doshi sold 4,000 shares of Entrada Therapeutics stock in a transaction dated Monday, June 27th. The shares were sold at an average price of $12.00, for a total transaction of $48,000.00. Following the completion of the transaction, the chief executive officer now directly owns 210,710 shares of the company’s stock, valued at $2,528,520. The disclosure for this sale can be found here. Insiders sold a total of 23,602 shares of company stock valued at $309,365 in the last ninety days. Corporate insiders own 7.22% of the company’s stock.

Entrada Therapeutics Price Performance

Entrada Therapeutics stock opened at $13.43 on Friday. Entrada Therapeutics, Inc. has a 12-month low of $5.12 and a 12-month high of $36.85. The company has a market capitalization of $421.27 million and a price-to-earnings ratio of -1.11. The firm’s fifty day moving average price is $12.63 and its 200 day moving average price is $9.90.

Entrada Therapeutics (NASDAQ:TRDAGet Rating) last released its quarterly earnings results on Thursday, August 11th. The company reported ($0.74) earnings per share (EPS) for the quarter.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group lifted their price target on shares of Entrada Therapeutics from $10.00 to $13.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 16th.

Entrada Therapeutics Company Profile

(Get Rating)

Entrada Therapeutics, Inc, a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1.

See Also

Want to see what other hedge funds are holding TRDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Entrada Therapeutics, Inc. (NASDAQ:TRDAGet Rating).

Institutional Ownership by Quarter for Entrada Therapeutics (NASDAQ:TRDA)

Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.